ΑD	,					

Award Number: W81XWH-07-1-0122

TITLE: Genetic Association Study of Ancestry-Matched African American Prostate Cancer Cases and Controls

PRINCIPAL INVESTIGATOR: William B. Isaacs, Ph.D.

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21218

Á

REPORT DATE: April 2010

TYPE OF REPORT: Ü^çã^å/å/Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
April 2010	Ü^çãr^åÆnnual	1 April 2009 – 31 March 2010
4. TITLE AND SUBTITLE		5a. CONTRACT NUMBER
Genetic Association Study of Ances	try-Matched African American Prostate Cancer	5b. GRANT NUMBER
Cases and Controls		W81XWH-07-1-0122
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)		5d. PROJECT NUMBER
William B. Isaacs	5e. TASK NUMBER	
		SC WORK UNIT NUMBER
E M-11		5f. WORK UNIT NUMBER
E-Mail: ¸ãrææs&∙Ob@(ãȰåĭ		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT NUMBER
Johns Hopkins University School of	Medicine	
Baltimore, MD 21218		
9. SPONSORING / MONITORING AGENCY		10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and M		
Fort Detrick, Maryland 21702-5012		
		11. SPONSOR/MONITOR'S REPORT
		NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATE	EMENT	

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

African American men have the highest incidence and mortality from prostate cancer in the world. Multiple reasons have been postulated to explain these findings although the definitive reasons for this are unknown. While both environmental and genetic factors may contribute to prostate cancer susceptibility, results from multiple studies consistently implicate a strong genetic component of this cancer. However, a specific gene which is consistently and reproducibly associated with prostate cancer risk in any population has not been identified. Association studies examining the frequency of common but specific genetic variants in study populations with and without a particular disease (i.e. case-control) is a powerful way to detect the influence of common genetic variants capable of affecting disease risk. While these types of studies are powerful, they are not without limitations, including the tendency to be confounded due to population stratification (a critical issue in admixed populations like African American), and the requirement for large, well matched, and well characterized study populations. While there has been extensive use of case control studies to identify genetic risk variants in Caucasian populations, corresponding studies in the African American prostate cancer population have been less extensive, typically being much smaller than the Caucasian counterparts, with little or no efforts to address the critical issue of population stratification as a confounder. It is now quite clear that unless cases are well matched to controls in terms of genetic heterogeneity in such studies, spurious associations will and undoubtedly have been observed and reported. In this study we use Ancestry Informative Markers (AIM) to match African American prostate cancer cases and controls for the purposes of performing association studies without confounding by population stratification. After this matching, we have identified and confirmed several prostate cancer susceptibility loci in this study population, on chro

15. SUBJECT TERMS

African American, Ancestry, genetics, Susceptibility

16. SECURITY CLAS	SIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU	ĵ	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction	5
Body	5
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusion	6
References	NA
Appendices	NA

INTRODUCTION

African American men have the highest incidence and mortality from prostate cancer in the world. Multiple reasons have been postulated to explain these findings including access to care, attitudes about care, socioeconomic and education differences, differences in type and aggressiveness of treatment, dietary, and genetic differences, although the definitive reasons for this are unknown. Indeed, the reasons why any prostate cancers occur are incompletely understood, and the only consistent risk factors identified for prostate cancer in addition to race are age and family history. While both environmental and genetic factors may contribute to prostate cancer susceptibility, results from multiple studies consistently implicate a strong genetic component of this cancer, with an estimated heritability of 42%, the highest among all common cancers. However, despite years of extensive effort by multiple research groups world wide, a specific gene which is consistently and reproducibly associated with prostate cancer risk in any population has not been identified. Association studies examining the frequency of common but specific genetic variants in study populations with and without a particular disease (i.e. case-control) is a powerful way to detect the influence of common genetic variants capable of affecting disease risk. While these types of studies are powerful, they are not without limitations, including the tendency to be confounded due to population stratification (a critical issue in admixed populations like African American), and the requirement for large, well matched, and well characterized study populations. While there has been extensive use of case control studies to identify genetic risk variants in Caucasian populations, corresponding studies in the African American prostate cancer population have been less extensive, typically being much smaller than the Caucasian counterparts, with little or no efforts to address the critical issue of population stratification as a confounder. It is now quite clear that unless cases are well matched to controls in terms of genetic heterogeneity in such studies, spurious associations will and undoubtedly have been observed and reported. In this study we use Ancestry Informative Markers (AIMs) to match African American prostate cancer cases and controls for the purposes of performing association studies without confounding by population stratification. We have identified and confirmed several prostate cancer susceptibility loci in these studies, on chromosomes 3, 8 and 17. These and other ongoing studies will provide unprecedented insight into the role of inherited factors in prostate carcinogenesis in African Americans.

BODY: To date, we have genotyped 58 AIMs in our study population. Genotyping this matched case control population for SNPs led to the discovery of an additional prostate cancer susceptibility locus at 8q24 (rs16901979) (Gudmundsson et al 2007). The risk allele ("A") at this locus is present in 50% of our African American cases, compared to 42% of controls. Importantly, this locus also shows association with risk for prostate cancer in European Americans although the risk allele is much less common in this population (~3% in controls, ~6% in cases); the OR of ~1.8 for this latter population is the largest effect observed to date for any SNP. These data indicate that the same locus can affect risk of prostate cancer in multiple different ancestral populations, although the effects and risk allele frequencies may be very different. More recently, we completed genotyping of an additional 7 SNPs on chromosome 17 in our matched African American case control population (Sun et al 2008). These analyses provided the first evidence that SNPs at 17q12 are associated with risk of prostate cancer in African Americans. In this case the risk allele (T at rs4430796) is less common in African Americans than it is in European Americans.

To address the general question of whether or not prostate cancer risk alleles identified in European Americans are also associated with risk in African Americans, we evaluated 20 known risk SNPs in 868 African American prostate cancer cases and 878 controls (Xu et al 2009). For 17 of these 20 SNPs, implicated risk-associated alleles were found to be more common in these AA cases than controls, significantly more than expected under the null hypothesis (P = 0.03). A multivariate analysis of additional SNPs across the broader 8q24 region revealed three independent prostate cancer risk-associated SNPs, including rs16901979, rs13254738, and rs10086908. The first two SNPs were approximately 20 kb apart and the last SNP, a novel finding from this study, was approximately 100 kb centromeric to the first two SNPs. These results suggest that a systematic evaluation of regions harboring known prostate cancer risk SNPs implicated in other races is an efficient approach to identify risk alleles for AA. However,

studies with larger numbers of AA subjects are needed, and this has required a major collaborative effort to combine multiple AA study populations. Such a study has now been performed and reported by Haiman et al (2011). This study included our AA subjects in a combined analysis of 3425 AA prostate cancer cases and 3290 AA controls. This study validated and improved upon markers of risk in some regions that better define the association with prostate cancer in African Americans. The findings with variants at 8q24 reinforce the importance of this region as a major risk locus for prostate cancer in men of African ancestry.

It has become clear that many men are diagnosed with and treated for prostate cancer that is destined never to progress. While the extent of this over-diagnosis problem is less clear in the African American population, it is evident that the identification of SNPs with prognostic significance would be of value for essentially all male populations. To address this issue we are continuing our search for risk SNPs which have prognostic significance in African American men.

KEY RESEARCH ACCOMPLISHMENTS:

- Our African American case control population has been genotyped for a panel of AIMs
- · Matching of cases and controls based on average percent African American ancestry has been accomplished
- Genotyping of 8q24 markers in this population led to the discovery of a novel prostate cancer risk variant (rs16091970) that is reproducibly associated with prostate cancer in African American men
- Genotyping of 17q12 markers in this population provided the first demonstration that rs4430796 is associated with prostate cancer risk in African American men.
- Genotyping of 20 SNPs markers in this population provided the first systematic analysis in African Americans of SNPs shown to be associated with prostate cancer risk in men of European descent.
- Our African American case control population was part of a large analysis fine mapping and refining the role of SNPs in prostate cancer risk in this population
- A summary of the progress on this project was presented at the IMPACT meeting in Florida in Spring 2011.

REPORTABLE OUTCOMES

Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.

Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan D, Carpten JD, Grönberg H, Xu J, Chang BL, Partin AW, Walsh PC, Isaacs WB, Zheng SL. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008 May 15;68(7):691-7

Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, Sun J, Isaacs SD, Wiley KE, Kim ST, Hsu FC, Wu W, Torti FM, Walsh PC, Chang BL, Isaacs WB. Prostate Cancer Risk Associated Loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009;18(7):2145-9.

Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Chanock SJ, Kolb S, Signorello LB, Yamamura Y, Neslund-Dudas C, Thun MJ, Murphy A, Casey G, Sheng X, Wan P, Pooler LC, Monroe KR, Waters KM, Le Marchand L, Kolonel LN, Stram DO, Henderson BE. Characterizing genetic risk at known prostate cancer susceptibility Loci in african americans. PLoS Genet. 2011 May;7(5):e1001387. Epub 2011 May 26.

CONCLUSIONS

Ancestry mapping of African American prostate cancer cases and controls allows for the identification and characterization of genetic risk factors that are significantly and reproducibly associated with prostate cancer risk in this high risk population.